GSK-3 inhibition: achieving moderate efficacy with high selectivity.
about
Lupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice.Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis.QSAR studies in the discovery of novel type-II diabetic therapies.Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Recent advances in understanding the cellular roles of GSK-3.Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
P2860
Q30361236-0459A63F-42A3-4AC1-8433-AFA7A7CF5300Q35942258-E43AE21A-D311-430C-809A-7E381DDCA3C8Q36850239-0A23C6CE-FF6B-4189-8227-F5FA40416433Q38630598-D0EC8012-3B41-485B-AA80-9D56E4732825Q39003757-D6F478DB-2949-45AE-8F95-CAEEE07236AAQ39181126-0113FCD9-BABF-48A8-9BCD-C3650DE7E7A2Q48447516-A927C7EC-0E12-42F9-938E-362AF56243F3
P2860
GSK-3 inhibition: achieving moderate efficacy with high selectivity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
GSK-3 inhibition: achieving moderate efficacy with high selectivity.
@en
type
label
GSK-3 inhibition: achieving moderate efficacy with high selectivity.
@en
prefLabel
GSK-3 inhibition: achieving moderate efficacy with high selectivity.
@en
P1476
GSK-3 inhibition: achieving moderate efficacy with high selectivity.
@en
P2093
Avital Licht-Murava
Limor Avrahami
P304
P356
10.1016/J.BBAPAP.2013.01.016
P407
P577
2013-01-29T00:00:00Z